Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
hVIVOOPORF +27.29%48 3-Year Book Growth Rate is 23.10% as of Dec. 2025, which is 11% below its 10-year median of 25.85. GuruFocus rates OPORF with a GF Score™ of 48/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, hVIVO ranks better than 90.05% on this metric.
During the past 12 months, hVIVO's average Book Value per Share Growth Rate was -15.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 23.10% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 16.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of hVIVO was 91.30% per year. The lowest was -58.00% per year. And the median was 25.85% per year.
hVIVO (OTCPK:OPORF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
hVIVO 3-Year Book Growth Rate Related Terms
OPORF vs TMO, DHR, NTRA: 3-Year Book Growth Rate Comparison
For the Diagnostics & Research subindustry, hVIVO's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
hVIVO 3-Year Book Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where hVIVO's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 23.10% mean?
hVIVO (OPORF) has a 3-Year Book Growth Rate of 23.10% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for hVIVO and its competitors. This is 11% below median its historical median of 25.85. According to the industry distribution chart, hVIVO ranks #19 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 9.9%.
Is hVIVO's 3-Year Book Growth Rate too high?
hVIVO's current 3-Year Book Growth Rate of 23.10% is 11% below median its 10-year median of 25.85. Based on the distribution chart, hVIVO ranks #19 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, hVIVO has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does hVIVO's 3-Year Book Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, hVIVO ranks #19 out of 191 companies for 3-Year Book Growth Rate. This places hVIVO in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Diagnostics & Research company?
A good 3-Year Book Growth Rate depends on the Medical Diagnostics & Research industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for hVIVO and its competitors. hVIVO's current 3-Year Book Growth Rate is 23.10%, which is 11% below median its own 10-year median of 25.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
hVIVO (OPORF) has a current 3-Year Book Growth Rate of 23.10%. The stock's GF Value™ is $0.25, compared to a current price of $0.11 — trading 56.2% below its estimated fair value. The current 3-Year Book Growth Rate is 23.10%, which is 11% below median its 10-year median of 25.85. hVIVO's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For hVIVO (OPORF), the current 3-Year Book Growth Rate is 23.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is hVIVO (OPORF) Overvalued in 2026?
Based on GuruFocus' analysis, hVIVO stock appears to be undervalued.
The current stock price of $0.11 is trading 56.2% below its estimated GF Value™ of $0.25.
Key valuation signals for OPORF:
3-Year Book Growth Rate: 23.10% (11% below median its 10-year median of 25.85)
GF Value™: $0.25 vs. price of $0.11 (56.2% below fair value)
No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
48GF Score
Get the complete analysis for OPORF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPORF has been successfully added to your 
